Menu
  • About us
  • Our partners
  • Careers
  • News & events
  • Publications, posters and patents
  • Contact us
  • About us
  • Our partners
  • Careers
  • News & events
  • Publications, posters and patents
  • Contact us
Search
BioFocus
Accelerating Drug Discovery
Tel: +44 1799 533500
  • Home
  • Drug discovery capabilities
  • Therapeutic area expertise
  • Academic Engagement
In this section
  • News
  • Events
  • Webinars
  • Newsletters
  • Register

Archive

  • 2013
    • BioFocus launches Academic Engagement initiative
    • BioFocus extends its collaboration with The Michael J. Fox Foundation
    • Peter Rehse joins BioFocus as Senior Director, Structural Biology
    • BioFocus expands ion channel offering through agreement with ChanTest
  • 2012
    • BioFocus achieves milestone in its drug discovery collaboration with UCB
    • Activiomics signs research agreement with Kyowa Hakko Kirin as part of its strategic partnership with BioFocus
    • Galapagos subsidiary BioFocus and Ono sign a drug discovery agreement in the Field of CNS Disorders
    • BioFocus expands its drug discovery offering with proteomics technology from Activiomics
    • BioFocus selects Titian’s Mosaic™ software to provide optimized screening services
    • Ono and Galapagos subsidiary BioFocus sign an additional target discovery agreement in the field of allergic disease
    • BioFocus and Argenta announce drug discovery collaboration with AstraZeneca in respiratory and inflammatory disease
    • Almirall and BioFocus enter research alliance
  • 2011
    • BioFocus creates novel diverse screening library
    • Almirall and BioFocus announce collaboration to find new hit compounds against key targets
    • BioFocus announces second extension to collaboration with Chiesi
    • Argenta and BioFocus announce two-year extension of drug discovery collaboration with Genentech
    • BioFocus and InterMed Discovery announce Marketing Collaboration
    • BioFocus enters collaboration with Michael J. Fox Foundation
    • BioFocus extends collaboration with Usher III Initiative
    • Evotec acquires compound management business from Galapagos
    • Astellas Pharma and BioFocus sign target discovery agreement
    • BioFocus delivers validated oncology targets to Janssen
    • BioFocus and Almac collaborate to offer fluorescent lifetime assays
    • University of Nottingham and BioFocus sign compound management agreement
    • BioFocus leads compound library market with innovative business model
    • Lundbeck Research USA, Inc. and BioFocus sign compound management agreement
    • Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease
  • 2010
    • BioFocus extends collaboration with Amgen into 2012
    • BioFocus extends collaboration with Chiesi
    • BioFocus and the National Cancer Institute sign compound management agreement
    • BioFocus signs compound management agreement with eMolecules, Inc.
    • BioFocus launches new compound libraries
    • Argenta expands collaboration with Genentech to include BioFocus
    • BioFocus and Usher III Initiative, Inc. announce collaboration
    • BioFocus and University of Bristol enter drug discovery collaboration in chronic pain
    • NIH extends agreement with BioFocus until end 2012
    • BioFocus renouvelle son agrément CIR (Crédit Impôt Recherche)
    • BioFocus renews C.I.R. (French Research Tax Credit) accreditation
    • BioFocus and CHDI Foundation, Inc. enter new five-year collaboration for Huntington’s disease therapeutics
    • BioFocus launches four compound libraries targeting kinases and protein-protein interactions
    • Today, Galapagos announced the purchase of Argenta Discovery 2009 Ltd.
    • BioFocus achieves €1.6 M in payments
    • TB Alliance and BioFocus sign compound management agreement
  • 2009
    • Doris Hafenbradl joins BioFocus as Senior Director, Biology and Natural Products
    • BioFocus and DiscoveRx announce a co-marketing agreement for GPCR screening
    • BioFocus launches www.SilenceSelect.com microsite
    • BioFocus DPI announces expanded drug discovery collaboration with Schering-Plough
    • BioFocus DPI launches compound library targeting protein-protein interactions plus three new kinase libraries
    • BioFocus DPI and Procter & Gamble sign compound management agreement
    • BioFocus DPI and Oncodesign forge alliance to provide integrated oncology drug discovery services
    • Dates announced for free GPCR conference
    • Institute for OneWorld Health Announces Successful Collaboration to Fight Neglected Diarrheal Diseases in Developing Countries
    • BioFocus DPI launches six new SoftFocus libraries
    • BioFocus DPI to apply TET Technology in high-throughput screening campaigns
    • BioFocus DPI enhances high-throughput screening library
    • BioFocus DPI and Medicines for Malaria Venture collaborate to identify anti-malarial compounds
    • Royal Approval for Chesterford Research Park
    • BioFocus DPI enhances ADME/PK Laboratory bioanalytical capabilities
    • BioFocus DPI extends drug discovery collaboration with Lilly
    • BioFocus DPI enhances high-content screening capabilities
  • 2008
    • Galapagos extends drug discovery collaboration with Amgen into 2010
    • Scott Snyder to head BioFocus DPI Compound Management
    • BioFocus DPI and Dart Neuroscience LLC sign drug discovery and compound management agreements
    • Galapagos and Merck Serono enter new collaboration agreements
    • BioFocus DPI and ZoBio announce marketing agreement
    • Galapagos sells San Diego chemistry facility to ChemVentures
    • Galapagos and CHDI enter new collaboration agreements
    • Enhanced decision support software streamlines data access and integration
    • BioFocus DPI launches seven new libraries including its first libraries targeting proteases
    • Cutting-edge meeting on ion channel drug discovery
    • OneWorld Health and BioFocus DPI expand collaboration to develop new drugs for the treatment of childhood diarrheal diseases
    • BioFocus DPI adds structural biology to its drug discovery services
    • UCB transfers UK-based medicinal chemistry program to BioFocus DPI
    • BioFocus DPI transfers predictive drug discovery databases to EMBL’s European Bioinformatics Institute
    • NIH extends agreement with BioFocus DPI
    • Boehringer Ingelheim licenses drug targets from autoimmune collaboration with BioFocus DPI
    • BioFocus DPI signs new compound management agreement
    • California stem Cell and BioFocus DPI to collaborate in ALS Association-funded research using human motor neurons
    • BioFocus DPI to perform medicinal chemistry services for UCL research project
    • Galapagos and Allergan enter drug discovery collaboration
    • BioFocus DPI releases five new compound libraries
    • BioFocus DPI launches ‘Intelligent Screening’ platform at SBS
    • BioFocus DPI takes global license for Cresset’s molecular field software
    • BioFocus DPI to distribute NIH’s Clinical Compound Collection
    • BioFocus DPI launches ADME/PK service and software platform
    • Galapagos extends drug discovery collaboration with Lilly in nuclear hormone receptor research
    • Galapagos enters into oncology target discovery collaboration with Janssen Pharmaceutical
  • 2007
    • Galapagos and Cystic Fibrosis Foundation Therapeutics announce new drug discovery collaboration worth up to $8.1 million U.S. dollars
    • BioFocus DPI launches GPCR SARfari
    • BioFocus DPI enhances ADME optimization capabilities
    • BioFocus DPI launches five new compound libraries
    • Galapagos announces expanded relationship with AstraZeneca: BioFocus DPI to provide drug discovery services to US-site
    • Galapagos announces milestone in collaboration with Boehringer Ingelheim
    • BioFocus DPI launches Kinase SARfari knowledge base
    • Galapagos announces new collaboration agreements and a management appointment
    • Galapagos and AstraZeneca enter new drug discovery collaboration
    • Galapagos announces agreement worth up to €6.3 million with United States Environmental Protection Agency (EPA)
    • Galapagos signs two new drug discovery collaborations with Ono Pharmaceutical
    • Galapagos to supply chemical compound sets to Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica NV
    • Galapagos and the University of Bristol enter drug discovery collaboration
    • Galapagos expands and extends drug discovery collaboration with Amgen into 2008
  • 2006
    • Galapagos and The ALS Association announce €2.4 million target discovery alliance
    • Galapagos to acquire Inpharmatica
    • Galapagos awarded European Union grant
    • Galapagos extends target discovery alliance with Cystic Fibrosis Foundation Therapeutics
    • Galapagos announces natural compounds collaboration with LEO Pharma
    • Inpharmatica develops target-family specific knowledge base for Schering AG
    • Galapagos and OneWorld Health collaborate to develop new drugs for the treatment of diarrheal diseases
    • Galapagos announces new collaboration with AstraZeneca
    • Galapagos and Cellzome in kinase drug discovery collaboration
    • Galapagos completes acquisition of drug discovery service operations of Discovery Partners International
    • Galapagos expands chemistry services through contracts with Indian companies
    • Galapagos announces exclusive agreement with Upstate for marketing and sales of adenovirus products
    • Galapagos and Arthrogen enter target discovery alliance
    • Galapagos enters a three-year collaboration with Roche
    • Galapagos and BASF extend research collaborations
    • Galapagos and Cancer Research Technology announce new anti-cancer drug discovery collaboration
    • Galapagos enters new collaboration in autoimmune discovery research
    • Angus MacLeaod named Director of Medicinal Chemistry at BioFocus
Contact us

News & events

BioFocus selects Titian’s Mosaic™ software to provide optimized screening services

Tue 10 Jul 2012

As part of maintaining its position as a leading provider of screening services, BioFocus has selected Titian Software’s industry-leading Mosaic™ sample management software to provide fast and easy access to its 900,000 compounds, one of the largest HTS compound collections of any CRO in the world.

Titian’s Mosaic is capable of integrating with a range of automated robotic hardware and infrastructure, and will make it easy for BioFocus to extract and track compounds from its compound deck when screening for BioFocus’ worldwide clients. The new approach will optimize workflow efficiency with its clients, many of whom already use Mosaic. The software provides an up-to-the-minute status on the available inventory in real-time and automatically generates all required documentation.

Kate Hilyard, VP Biological Sciences of BioFocus commented: “During 2011 we enhanced our compound decks, and now for 2012 we have invested in the underlying software to manage these decks efficiently. Further developments in infrastructure and equipment are in the pipeline to support what will become a single, fully consolidated screening centre at our Chesterford Park site by the end of 2012.”

“With twelve years of experience working with most of the world’s leading pharma and biotech companies, Titian has become the go-to provider for compound management solutions, and we are delighted to be working on this project with BioFocus,” said Edmund Wilson, Titian’s CEO. “By offering a simple-to-use interface and by fully integrating with the company’s existing hardware, Mosaic will make the process of HTS screening for BioFocus’ clients much more efficient.”

About BioFocus

BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capability in neurodegenerative diseases, inflammatory diseases and with a growing track record of delivering candidates against rare and neglected diseases. BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client projects to deliver targets, hits, leads and candidate pre-clinical drugs. The company employs over 200 exceptionally qualified and industry experienced scientists at its three research centers in the UK, Switzerland and the Netherlands. Since its foundation in 1997, BioFocus has striven to produce high quality data for its clients and this quality is assured by ISO9001 qualification validated by regular, independent inspection of all BioFocus research centers.

About Titian

Trusted by pharma, biotech and academic institutions throughout the world, Titian Software improves the efficiency, throughput and data integrity of sample management in life science research. From enterprise-wide solutions to a single lab, Titian’s Mosaic software optimizes the tracking, ordering and preparation of small molecule compounds, biological samples and reagents. Mosaic is the leading sample management software in life sciences, and has been chosen by 13 of the top 20 pharma/biotech companies. To find out more about the Mosaic modular sample management software system and its applications, please visit the Titian Software website at www.titian.co.uk.

BioFocus® is a trademark of Galapagos NV and/or its affiliates © Copyright 2012 Galapagos NV.

Mosaic™ is a trademark of Titian Software Limited © 2010-2012 Titian Software Limited.

Back to listing

Contact us

Our website uses cookies to offer the best possible experience. By continuing to use the site you are agreeing to our usage of cookies. Find out more >

  • Sign up to our mailing list
  • Follow us on Twitter
  • Hogan Ralph Lauren Outlet Borsa Louis Vuitton Abercrombie Milano Borse Burberry

BioFocus®, SoftFocus®, Galapagos®, SilenceSelect® and FLeXSelect® ThemePair™, FieldFocus™, HDRA™. Helical Domain Recognition Analysis™, 2D Roadmap™, Thematic Analysis™, SFK™, SFI™, SFG™ and PrimePath™ are trademarks of Galapagos NV and/or its affiliates.

  • Terms and conditions
  • Privacy policy
  • Sitemap